Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Not applicable
Started
2022-01-01
Last updated
2025-12-11
Condition(s) studied
Soft Tissue SarcomaRetroperitoneal SarcomaRadiotherapy Side EffectUltra-hypofractionated RadiotherapyStereotactic Ablative Radiotherapy
Investigational drug(s) / intervention(s)
ultra-hypofractionated radiotherapy
ultra-hypofractionated radiotherapy: stereotactic ablative radiotherapy with 25 to 50Gy in five fractions given preoperatively
Study summary
To investigate the feasibility and peri-operative complications of preoperative hypo-fractionated radiotherapy followed by surgery for retroperitoneal sarcoma
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Primary soft tissue sarcoma of retroperitoneal or infra-peritoneal spaces of pelvis
* Sarcoma not originated from bone structure, abdominal or gynecological viscera
* All disease can be included safely within one radiotherapy field
* Absence of extension through the sciatic notch or across the diaphragm
* Histologically proven, excluding the following subtypes: Gastro-intestinal stromal tumors (GIST), rhabdomyosarcoma, PNET or other small round blue cells sarcoma, osteosarcoma or chondrosarcoma, aggressive fibromatosis, sarcomatoid or metastatic carcinoma
* ECOG performance status 0 to 2
* American Society of Anesthesiologist (ASA) score ≤2
* Normal renal function: Calculated Creatinine Clearance ≥50ml/min(by Cockcroft-Gault formula)and functional contralateral kidney by differential renal isotope scan
* Normal bone marrow and hepatic function.
* Contraception was needed for female patients of child-bearing age, or male patients whose partner had child-bearing age
* expected life expectancy longer than 5 years
* Written consent form was given prior to treatment
* Can safely be treated by radiotherapy and surgery
Exclusion Criteria:
* metastatic disease
* Tumor was previously treated by radiotherapy
* Involvement of liver, pancreatic head or duodenum
Primary outcome measure(s)
Peri-operative complications — From surgery date up to 7 days later The proportion of patients who suffer from
Trial sites (1)
Facility
City
Region
Status
Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences
Beijing
Beijing Municipality
Recruiting
More Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.